Showing 1 - 8 results of 8 for search 'Akhavanpoor M', query time: 0.03s Refine Results
  1. 1
    CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions

    CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions by Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C

    Published 2014-11-01
    Get full text
    Article
  2. 2
    PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels

    PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels by Erbel C, Achenbach J, Akhavanpoor M, Dengler TJ, Lasitschka F, Gleissner CA, Bea F, Katus HA, Szabo G

    Published 2011-08-01
    Get full text
    Article
  3. 3
    Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

    Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions by Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C

    Published 2014-05-01
    Get full text
    Article
  4. 4
    Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

    Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation by Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

    Published 2015-02-01
    Get full text
    Article
  5. 5
    Proinflammatory and prothrombotic effects on human vascular endothelial cells of Immune-cell-derived LIGHT

    Proinflammatory and prothrombotic effects on human vascular endothelial cells of Immune-cell-derived LIGHT by Celik S, Shankar V, Richter A, Hippe H-J, Akhavanpoor M, Bea F, Erbel C, Urban S, Blank N, Wambsganss N, Katus HA, Dengler TJ

    Published 2009-04-01
    Get full text
    Article
  6. 6
    Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

    Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen by Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

    Published 2014-09-01
    Get full text
    Article
  7. 7
    Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

    Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy by Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

    Published 2014-12-01
    Get full text
    Article
  8. 8
    Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

    Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart... by Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

    Published 2016-02-01
    Get full text
    Article

Search Tools: